3B Blackbio (3BBLACKBIO) | Financial Analysis & Statements
3B Blackbio Diagnostics Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Sep 2025Income Metrics
Revenue
339.0M
Gross Profit
246.5M
72.71%
Operating Income
141.5M
41.74%
Net Income
150.4M
44.36%
EPS (Diluted)
₹17.55
Balance Sheet Metrics
Total Assets
3.4B
Total Liabilities
368.7M
Shareholders Equity
3.0B
Debt to Equity
0.12
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Sep 30, 2025
Annual Income Flow
2025
3B Blackbio Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 964.7M | 741.2M | 618.4M | 806.5M | 2.3B |
| Cost of Goods Sold | 256.5M | 218.5M | 179.2M | 316.2M | 515.7M |
| Gross Profit | 708.2M | 522.8M | 439.1M | 490.2M | 1.8B |
| Gross Margin % | 73.4% | 70.5% | 71.0% | 60.8% | 77.3% |
| Operating Expenses | |||||
| Research & Development | 5.1M | 7.0M | 8.4M | 3.6M | 2.5M |
| Selling, General & Administrative | 22.2M | 9.9M | 15.5M | 8.1M | 7.3M |
| Other Operating Expenses | 98.3M | 102.4M | 66.3M | 59.3M | 158.3M |
| Total Operating Expenses | 125.6M | 119.3M | 90.3M | 71.1M | 168.1M |
| Operating Income | 493.2M | 322.4M | 286.3M | 364.3M | 1.5B |
| Operating Margin % | 51.1% | 43.5% | 46.3% | 45.2% | 65.9% |
| Non-Operating Items | |||||
| Interest Income | 84.2M | 63.3M | 38.7M | - | - |
| Interest Expense | 1.1M | 1.2M | 2.0M | 1.1M | 2.3M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 640.0M | 443.3M | 353.1M | 432.2M | 1.5B |
| Income Tax | 163.1M | 122.3M | 93.7M | 110.2M | 381.7M |
| Effective Tax Rate % | 25.5% | 27.6% | 26.5% | 25.5% | 25.1% |
| Net Income | 476.9M | 321.0M | 259.4M | 322.0M | 1.1B |
| Net Margin % | 49.4% | 43.3% | 41.9% | 39.9% | 50.2% |
| Key Metrics | |||||
| EBITDA | 591.1M | 396.5M | 335.9M | 440.0M | 1.5B |
| EPS (Basic) | ₹55.66 | ₹37.46 | ₹30.27 | ₹43.40 | ₹151.66 |
| EPS (Diluted) | ₹55.66 | ₹37.46 | ₹30.27 | ₹43.40 | ₹151.66 |
| Basic Shares Outstanding | 8568400 | 8568400 | 8566370 | 7491820 | 7508100 |
| Diluted Shares Outstanding | 8568400 | 8568400 | 8566370 | 7491820 | 7508100 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
3B Blackbio Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 117.1M | 129.2M | 52.4M | 272.9M | 338.1M |
| Short-term Investments | 563.6M | 486.6M | 532.9M | 255.6M | 330.9M |
| Accounts Receivable | 365.2M | 362.5M | 339.4M | 299.8M | 347.9M |
| Inventory | 87.4M | 84.3M | 80.4M | 74.3M | 48.7M |
| Other Current Assets | 1.0K | 1.0K | 129.6M | 151.5M | 435.4M |
| Total Current Assets | 1.3B | 1.2B | 1.1B | 815.4M | 1.2B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 85.4M | 78.9M | 77.4M | 69.8M | 51.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 968.0K | 546.0K | -1.0K | -4.9M | -1 |
| Total Non-Current Assets | 1.6B | 1.2B | 998.2M | 1.1B | 751.4M |
| Total Assets | 3.0B | 2.5B | 2.1B | 1.9B | 1.9B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 19.7M | 39.5M | 33.7M | 35.4M | 29.5M |
| Short-term Debt | 0 | 632.0K | 11.2M | 16.9M | 9.9M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.6M | 4.6M | 3.9M | 8.5M | 8.5M |
| Total Current Liabilities | 185.9M | 175.3M | 141.8M | 169.0M | 429.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 3.1M | 7.9M | 9.1M | 8.4M | 10.2M |
| Deferred Tax Liabilities | 58.2M | 43.1M | 29.2M | 22.7M | 12.4M |
| Other Non-Current Liabilities | -1.0K | 2.0K | 1.3M | 17.0K | 293.1K |
| Total Non-Current Liabilities | 61.3M | 51.0M | 39.6M | 31.1M | 22.8M |
| Total Liabilities | 247.1M | 226.3M | 181.5M | 200.2M | 452.5M |
| Equity | |||||
| Common Stock | 85.7M | 85.7M | 85.7M | 74.9M | 74.9M |
| Retained Earnings | 2.5B | 2.1B | 1.8B | 1.4B | 1.1B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 2.7B | 2.3B | 2.0B | 1.7B | 1.5B |
| Key Metrics | |||||
| Total Debt | 3.1M | 8.5M | 20.3M | 25.3M | 20.0M |
| Working Capital | 1.1B | 1.1B | 1.0B | 646.4M | 754.2M |
Balance Sheet Composition
3B Blackbio Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 640.0M | 443.3M | 353.1M | 432.2M | 1.5B |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -21.1M | -98.5M | -23.8M | 306.5M | -533.5M |
| Operating Cash Flow | 620.0M | 342.7M | 331.3M | 739.8M | 989.1M |
| Investing Activities | |||||
| Capital Expenditures | -9.0M | -5.1M | -20.2M | -22.6M | -16.8M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -329.4M | -198.1M | - | -338.3M | -685.3M |
| Investment Sales | - | 0 | 144.6M | 0 | - |
| Investing Cash Flow | -338.5M | -203.2M | 124.9M | -360.8M | -702.6M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -25.7M | -21.9M | -44.4M | -154.6M | - |
| Debt Issuance | - | - | 737.0K | 7.0M | - |
| Debt Repayment | -5.4M | -13.1M | -5.7M | -1.8M | -15.2M |
| Financing Cash Flow | -31.1M | -37.0M | -48.7M | -149.6M | -13.4M |
| Free Cash Flow | 424.5M | 264.4M | 182.6M | 350.6M | 958.4M |
| Net Change in Cash | 250.4M | 102.5M | 407.5M | 229.4M | 273.2M |
Cash Flow Trend
3B Blackbio Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
20.80
Price to Book
3.89
Price to Sales
9.21
PEG Ratio
0.34
Profitability Ratios
Profit Margin
44.56%
Operating Margin
42.39%
Return on Equity
17.60%
Return on Assets
16.13%
Financial Health
Current Ratio
6.25
Debt to Equity
0.09
Beta
0.47
Per Share Data
EPS (TTM)
₹66.57
Book Value per Share
₹355.75
Revenue per Share
₹151.86
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| 3BBLACKBIO | 11.1B | 20.80 | 3.89 | 17.60% | 44.56% | 0.09 |
| Biocon | 566.5B | 71.84 | 1.68 | 3.66% | 3.59% | 50.02 |
| OneSource Specialty | 202.8B | 936.63 | 3.11 | -0.31% | 1.42% | 21.93 |
| Zota Health Care | 39.4B | -62.53 | 12.61 | -24.83% | -15.37% | 56.90 |
| Dishman Carbogen | 26.5B | 22.30 | 0.42 | 0.06% | 4.25% | 40.20 |
| Panacea Biotec | 21.8B | 182.62 | 2.65 | -1.01% | -1.29% | 2.79 |
Financial data is updated regularly. All figures are in the company's reporting currency.





